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Abstract 
We evaluated a non-invasive method for predicting the ovarian function of premenopausal breast cancer patients 
with amenorrhoea after chemotherapy. A total of 34 patients had ovarian function, whereas 56 had no ovarian 
function. Logistic regression analysis indicated that age (P = 0.034; hazards ratio [HR], 0.29; confidence interval [CI], 
0.091–0.910), follicle-stimulating hormone (P = 0.032; HR 0.97; CI 0.944–0.997) and oestradiol (P = 0.047; HR 1.01; CI 
1.000–1.015) were independent influencing factors that determine ovarian function. The ovarian function score (OFS) 
(P < 0.001; HR 48.00; CI 10.174–226.452) was obtained through a comprehensive analysis of these three variables, and 
it could more effectively predict ovarian function. According to receiver operating characteristic curve analysis, the 
OFS had the highest values compared with the other three variables (sensitivity, 94.6 %; specificity, 79.3 %). The OFS is 
simple and easy to use; thus, it is expected to become a new method for determining drug-induced amenorrhoea in 
women with breast cancer. Ovarian function likely still exists if the OFS is ≤1.
Keywords: Breast cancer, Ovarian function, Amenorrhoea, Ovariectomy, Sex hormone
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Endocrine therapy is one of the important systemic treat-
ment methods conventionally recommended for patients 
with breast cancer with a positive hormone receptor, 
and it can effectively reduce mortality due to hormone-
dependent breast cancer and its recurrence rates (Jordan 
2014; Davies et al. 2013).
Oestrogen in premenopausal women mainly comes 
from the ovaries, and its production is affected by gon-
adotropins. Premenopausal breast cancer patients often 
choose tamoxifen (TAM), a selective oestrogen receptor 
modulator, as their first-line endocrine treatment. Clini-
cal studies such as ATAC (Cuzick et  al. 2010) and BIG 
1-98 (Breast International Group (BIG) 1-98 Collabo-
rative Group et  al. 2005) have confirmed that the cura-
tive effect of aromatase inhibitors (AIs) in patients with 
breast cancer is superior to TAM. However, AIs can 
only block the synthesis of exogenous oestrogen outside 
the ovaries in women, e.g., by blocking the adrenal cor-
tex or peripheral tissues (i.e., the liver, fat and muscle), 
to convert testosterone into oestradiol (E2) and andros-
tenedione into oestrone. Thus, AIs can only be used for 
patients with breast cancer with ovarian function failure. 
Prediction of ovarian function in premenopausal breast 
cancer patients with amenorrhoea after chemotherapy is 
important.
Periodic monitoring detection of serum sex hormone 
levels is often used to clinically evaluate ovarian func-
tion, as serum E2 and follicle-stimulating hormone (FSH) 
levels are used in evaluating menopausal status (Yu et al. 
2010). About 10 % of patients with amenorrhoea resume 
bleeding 2 years after chemotherapy (Sukumvanich et al. 
2010). Meanwhile, TAM can influence the ovarian func-
tion of premenopausal patients, with several clinical trials 
confirming that it may induce amenorrhoea (Tham et al. 
2007; Ganz et al. 2011; Jung et al. 2010). Researchers have 
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found that AIs should be avoided in patients with amen-
orrhoea <48 years who are receiving TAM, despite meno-
pausal manifestations and sex hormone level changes 
(Guerrero et  al. 2013). About 25–30  % of amenorrheic 
breast cancer patients’ ovarian function may be misdiag-
nosed when determined through their menopausal sta-
tus and sexual hormones (Smith et al. 2006; Henry et al. 
2013). This suggests that it is very difficult to determine 
ovarian function accurately.
Ovarian pathology results are the gold standard, as 
they accurately reflect ovarian functions. In this retro-
spective study, we collected clinical and pathological 
data of patients with breast cancer who developed amen-
orrhoea after chemotherapy and underwent ovariectomy 
for their condition. We observed the largest sectional 
area of the ovary and determined whether it had func-
tion by examining the ovarian pathology results. The 
relationship between the clinical follow-up data before 
ovariectomy and the ovarian function was tested. The 
present study attempted to determine more reliable clin-
ical indexes and a non-invasive method for evaluating 
ovarian function.
Methods
Data of patients initially diagnosed with breast cancer in 
West China hospital of Sichuan University during 2008 
to 2013 were collected. Patients with normal menstrua-
tion before breast cancer treatment, with premenopausal 
level of sexual hormones (hormones are normal before 
chemotherapy: FSH ≤ 40 IU/L, E2 ≥ 10 pg/mL) and with 
cessation of menstruation during chemotherapy; those 
with a positive hormone receptor (positive for oestrogen, 
progesterone, or both); and those treated with TAM after 
completing chemotherapy were included. Patients who 
used endocrine therapy drugs other than TAM; those 
who used drugs, within 6 months, that may interfere with 
sexual hormone levels; and those who had already under-
gone hysterectomy were excluded.
Castration was performed for the following reasons: 
(Jordan 2014) breast cancer accompanied with distant 
metastasis during initial diagnosis; (Davies et  al. 2013) 
high recurrence risk with amenorrhoea after chemo-
therapy and menstruation resumption during follow-up; 
(Cuzick et al. 2010) recurrence or metastasis during the 
treatment process. All patients took TAM for less than 
5  years, and none desired fertility preservation. After a 
discussion with their doctors, the patients opted for ovar-
ian castration combined with AI treatment for better 
therapeutic effect. Because they refused to use drug cas-
tration due to financial burden or personal reasons (e.g., 
they could not receive long-term injections), they volun-
tarily chose to undergo oophorectomy.
Data collection
The following clinical data were collected from electronic 
medical records and follow-up databases of West China 
hospital of Sichuan University (follow-up once every 
3  months in the first year after breast cancer surgery 
and once every 6 months after the first year): age, body 
mass index, number of pregnancies, number of births, 
menarche age, tumour size, lymph node stage, hormone 
receptor status, immunochemical human epidermal 
growth factor receptor 2 (her-2) score, targeted therapy 
(herceptin, 8  mg/kg for the first time, 6  mg/kg after-
wards for maintenance every 3  weeks), chemotherapy 
cycle, chemotherapy regimen, duration of TAM admin-
istration, duration between completing chemotherapy 
and ovariectomy, ovarian cyst and its nature (e.g., meta-
static tumour of breast cancer; benign epithelial tumour; 
functional cysts, including follicular cysts and corpus 
luteum cysts), histological grade and the date when 
bleeding resumed. The following chemotherapy regi-
mens were used: without anthracycline and cyclophos-
phamide: taxanes (175 mg/m2) every 3 weeks; with either 
anthracycline or cyclophosphamide: taxotere (75  mg/
m2)  +  cyclophosphamide (600  mg/m2) every 3  weeks; 
epirubicin (100  mg/m2)  +  taxotere (75  mg/m2) every 
3 weeks; with both anthracycline and cyclophosphamide: 
epirubicin (100  mg/m2)  +  cyclophosphamide (830  mg/
m2) every 3  weeks; taxotere (75  mg/m2)  +  epirubicin 
(100  mg/m2)  +  cyclophosphamide (500  mg/m2) every 
3 weeks, fluorouracil (500 mg/m2) + epirubicin (100 mg/
m2)  +  cyclophosphamide (500  mg/m2) every 3  weeks, 
followed by taxotere (100  mg/m2) every 3  weeks. The 
dosage of TAM was 20 mg/day.
The FSH, luteinising hormone (LH) and E2 levels 
were assessed at each follow-up. If bleeding resumed in 
patients who had amenorrhoea after chemotherapy, the 
sexual hormone levels were reassessed on the second 
day of each menstrual cycle. The sex hormone levels 
were determined by chemiluminescence immunoassay 
(Roche E170; Roche Diagnostics, Mannheim, Germany), 
which defined postmenopausal hormone levels as an 
FSH > 26.1  IU/L; LH > 14.4  IU/L; E2 < 5 pg/mL. Ovar-
ian tissue was divided equally into two parts, and the 
pathological sections were assessed independently by two 
experienced pathologists. The ovary were determined to 
have developed ovarian follicles when ovarian pathology 
confirmed the existence of undegraded corpus luteum, 
the primary or secondary follicles, follicular cysts, corpus 
luteum cysts. When there were scattered and atretic fol-
licles and occasional primordial follicles, ovarian func-
tion was determined to have decreased without complete 
failure. The aforementioned situations represent existing 
ovarian function. The absence of such conditions was 
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identified as ovarian failure (Nichols et al. 2005; Ozdamar 
et al. 2005).
Ethics approval and consent to participate
This study was approved by the ethical committee of the 
West China hospital of Sichuan University.
Statistical analysis
Univariate analysis was performed to screen the vari-
ables that had a significant association with ovarian func-
tion. Categorical variables were analysed using Pearson’s 
χ2 test. Quantitative variables were analysed using t test. 
Ranked data were analysed using the Kruskal–Wallis 
test. If P  <  0.1, the variable was used in logistic regres-
sion analysis to analyse the independent factors to deter-
mine ovarian function. Receiver operating characteristic 
(ROC) curves were used to describe the optimal predic-
tion thresholds of the variables, and the area under the 
curve (AUC) indicated a factor’s predictive value for 
determining ovarian function. After performing multi-
variate analysis, the ROC curve was used to establish a 
simpler and easier scoring method.
Results
The clinical characteristics of these participants are 
shown in Table 1. Ninety patients were included. Thirty-
four patients had ovarian function, whereas 56 had no 
ovarian function. Variables with P < 0.1, as confirmed by 
univariate analysis, are shown in Table  1, including age 
(≥40 or <40 years, P = 0.002), tumour size (P = 0.013), 
lymph node stage (P  =  0.023), duration of TAM 
(P  =  0.035), duration between completing chemother-
apy and ovariectomy (P  =  0.046), LH (P  <  0.001), FSH 
(P < 0.001), E2 (P = 0.002) and ovarian cyst (P < 0.001).
After including the aforementioned variables, age 
(P = 0.034; hazards ratio [HR], 0.29; confidence interval 
[CI] 0.091–0.910), FSH (P =  0.032; HR 0.97; CI 0.944–
0.997) and E2 (P = 0.047; HR 1.01; CI 1.000–1.015) were 
independent influencing factors that could determine 
ovarian function (Table  2). The risk of ovarian failure 
increased when the patient’s age was ≥40 years, the FSH 
level increased, and the E2 level decreased. ROC analy-
sis showed that FSH ≤  23.8  IU/L and E2  >  13.5  pg/mL 
are the maximum efficiency cut-off levels for a functional 
ovary. The ovarian function score (OFS) was created, with 
points assigned to different variables: age, ≥40 years = 1, 
<40 years = 0; FSH, >23.8 IU/L = 1, ≤23.8 IU/L = 0; E2, 
>13.5 pg/mL = 1, ≤13.5 pg/mL = 0; OFS = age + FSH-
E2. Logistic regression analysis indicated that this new 
variable was associated with ovarian function (P < 0.001; 
HR 48.00; CI 10.174–226.452), and the ROC curve was 
generated. The OFS had the largest AUC (0.924) com-
pared with the AUCs of the other four variables and was 
more discriminating than age (P < 0.001) and FSH level 
(P = 0.001). ROC analysis indicated that OFS ≤ 1 is the 
maximum efficiency score for predicting ovarian func-
tion (sensitivity, 94.59  %; specificity, 79.25  %) (Table  3; 
Fig. 1). Table 4 shows the status of age, FSH level, and E2 
level when the ovaries were functional.
Discussion
According to the National Cancer Comprehensive 
Network, the criteria for determining postmenopau-
sal breast cancer include prior bilateral oophorectomy, 
>60, <60 years and amenorrhoea for ≥12 months in the 
absence of chemotherapy, TAM, toremifene, or ovarian 
suppression, and postmenopausal range of FSH and E2 
levels; if a patient <60 years is taking TAM or toremifene, 
the FSH and E2 levels should be in the postmenopausal 
range (National Comprehensive Cancer Network 2013). 
AI is foreseen to be prescribed as serial hormone meas-
urements showed FSH  >  40  UI/L and E2  <  10  pg/mL 
(Torino et al. 2014). However, for patients who use TAM, 
the accuracy of this method is limited and it cannot pre-
dict the state of ovarian function. Unfortunately, until 
now, ovarian function failure could not be accurately 
determined in menopausal patients with breast cancer 
after chemotherapy.
The ovarian function begins to decrease starting 
40  years old. Most women >40  years develop chemo-
therapy-induced amenorrhoea, but in patients <40 years, 
amenorrhoea lasts >6  months after chemotherapy and 
menstruation recovery often occurs during the follow-
up period (Walshe et  al. 2006; Minisini et  al. 2009). 
Multiple studies have suggested that the risk of ovarian 
failure after chemotherapy increases with age (Sonmezer 
and Oktay 2006; Marhhom and Cohen 2007). The inci-
dence of chemotherapy-induced menopause in patients 
<40 years (22–61 %) is lower than that in those >40 years 
(61–97  %) (Del Mastro et  al. 1997). The patients in our 
study were grouped by this cut-off age, and we found 
that age is an independent factor of ovarian function; in 
those >40  years, ovarian function decreased more than 
those <40 years (28.4 vs. 65.2 %). TAM could induce the 
negative feedback on pituitary gonadotropin because of 
its oestrogen-like effect (Jordan et  al. 1987). In patients 
who used TAM in our study, this may be because the 
drug interferes with sexual hormones and thus induces 
a decrease in the FSH level (Rossi et  al. 2009; Harper-
Wynne et al. 2002). An FSH level >23.8 IU/L in the OFS 
is the threshold used to determine non-functional ovaries 
and slightly lower than the recommended FSH reference 
value of >26.1  IU/L, according to the detection method 
used in this study.
Clinical studies have found that TAM can increase the 
E2 level, which may be due to the direct effect of TAM 
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Table 1 Participants’ clinical characteristics
Characteristic With ovarian  
function (n = 34)
Without ovarian  
function (n = 56)
P value
Age [% (years)] 0.002
 ≥40 (n = 67) 19 (28.4) 48 (71.6)
 <40 (n = 23) 15 (65.2) 8 (34.8)
BMI (kg/m2, mean ± SD) 0.136
 <24 (n = 65) 21 (32.3) 44 (67.7)
 24–28 (n = 20) 12 (60.0) 8 (40.0)
 ≥28 (n = 5) 1 (20) 4 (80)
Menarche age (years, mean ± SD) 13.6 ± 1.5 13.8 ± 1.5 0.692
No. of pregnancies (mean ± SD) 2.7 ± 1.5 2.8 ± 1.4 0.918
No. of births (mean ± SD) 1.1 ± 0.3 1.2 ± 0.6 0.414
Pathological classification (%) 0.450
Ductal carcinoma (n = 82) 31 (37.8) 51 (62.2)
Adenocarcinoma (n = 2) 0 (0) 2 (100.0)
Lobular carcinoma (n = 6) 3 (50.0) 3 (50.0)
Histological classification (%) 0.160
 1 (n = 2) 0 (0) 2 (100.0)
 2 (n = 35) 11 (31.4) 24 (68.6)
 3 (n = 53) 23 (43.4) 30 (56.6)
Tumor size 0.013
 T1 (n = 28) 15 (53.6) 13 (46.4)
 T2 (n = 52) 18 (34.6) 34 (56.4)
 T3 (n = 10) 1 (10.0) 9 (90.0)
Lymph node stage 0.023
 N0 (n = 20) 9 (45.0) 11 (55.0)
 N1 (n = 26) 15 (57.7) 11 (42.3)
 N2 (n = 18) 4 (22.2) 14 (77.8)
 N3 (n = 26) 6 (23.1) 20 (76.9)
ER status 0.839
 ER+ (n = 84) 31 (36.9) 53 (63.1)
 ER− (n = 6) 3 (50.0) 3 (50.0)
PR status 1.000
 PR+ (n = 78) 29 (37.2) 49 (62.8)
 PR− (n = 12) 5 (41.7) 7 (58.3)
HER-2 score (%) 0.515
 0 (n = 59) 21 (35.6) 38 (64.4)
 1 (n = 10) 5 (50.0) 5 (50.0)
 2 (n = 13) 3 (23.1) 10 (76.9)
 3 (n = 8) 5 (62.5) 3 (37.5)
Targeted therapy (%) 3 (33.3) 6 (66.7) 1.000
Chemotherapy regimens (%) 0.734
 Taxanes (n = 1) 0 (0) 1 (100.0)
 Anthracycline or cyclophosphamide (n = 31) 12 (38.7) 19 (61.3)
 Both anthracycline and cyclophosphamide (n = 58) 22 (37.9) 36 (62.1)
Chemotherapy cycle (mean ± SD) 6.5 ± 1.2 6.5 ± 1.3 0.676
Duration of tamoxifen (month, mean ± SD) 14.0 ± 13.0 9.9 ± 12.6 0.035
Duration between completing chemotherapy and ovariectomy 
(month, mean ± SD)
14.7 ± 12.7 10.7 ± 12.2 0.046
Ovarian cyst (%) 15 (44.1) 6 (10.7) <0.001
Metastatic tumor of breast cancer (n = 1) 1 (100) 0 (0)
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on ovarian granulosa cells (Metindir et al. 2005; Groom 
and Griffiths 1976). Mahran et  al. (2013) tested female 
Sprague–Dawley rats and found that radiation inhibited 
the rats’ ovarian function and oral TAM improved the 
insulin-like growth factor 1 levels of the follicles. Insulin-
like growth factor 1 acts on its receptors, promotes the 
proliferation of granulosa cells, and maintains the effects 
of aromatase, which may further promote follicle devel-
opment. It is possible that this is one of the mechanisms 
of ovarian hyperstimulation by TAM. Most studies have 
reported that TAM increases the risk of ovarian cyst in 
patients with breast cancer, and these cysts typically 
develop 3–11  months after undergoing treatment and 
are very rare after 2 years (Metindir et al. 2005; Partridge 
et  al. 2003; Mofrad et  al. 2010). TAM-induced ovarian 
cysts are usually functional ovarian cysts (physiological 
ovarian cysts) that are formed by the abnormal accumu-
lation of liquid in the follicle or corpus luteum, which is 
followed by the formation of follicular cysts or corpus 
luteum cysts (Cohen et al. 1999). In the present study, 17 
patients (50 %) with ovarian function had an ovarian cyst, 
including 13 (76.4 %) functional cysts, with cyst diame-
ters >5 cm in 2 cases. Additionally, patients with an ovar-
ian cyst usually had an increased oestrogen level as high 
as 1550 pg/mL. The increase in the E2 level and ovarian 
cysts may be due to ovarian hyperstimulation caused by 
TAM (Madeddu et al. 2014). In all the patients who used 
TAM, an E2 level ≥13.5 pg/mL in the OFS predicts ovar-
ian function, and this value is slightly higher than the 
standard mentioned above.
In our study, age, FSH level and E2 levels were associ-
ated with ovarian function, but the accuracy of predict-
ing ovarian function is limited by one of these indexes, as 
it is easy to misjudge ovarian function. The OFS consists 
of the three aforementioned clinical data. OFS ≤  1 can 
effectively predict ovarian function (sensitivity, 94.59  %; 
specificity, 79.25  %). Our study findings suggest that 
comprehensively combining these three variables greatly 
improves the accuracy of the prediction. The AUC of the 
Table 1 continued
Characteristic With ovarian  
function (n = 34)
Without ovarian  
function (n = 56)
P value
Benign epithelial tumor (n = 10) 4 (40) 6 (60)
Functional cysts (n = 10) 10 (100) 0 (0)
FSH
(IU/L, mean ± SD)
26.0 ± 2.0 45.2 ± 23.9 <0.001
LH
(IU/L, mean ± SD)
15.2 ± 10.2 24.2 ± 12.1 <0.001
E2
(pg/ml, mean ± SD)
156.3 ± 311.7 19.6 ± 57.4 0.002
Table 2 Evaluation of  the association between  the vari-
ables and ovarian function
HR 95 % CI P
Age 0.29 0.091–0.910 0.034
FSH 0.97 0.944–0.997 0.032
E2 1.01 1.000–1.015 0.047
OFS 48.00 10.174–226.452 <0.001
Table 3 Predictive value of each variable according to the 
receiver operating characteristic curve analysis
P value represent the significance between age/FSH/E2 and OFS
AUC Sn (%) Sp (%) P
Age 0.673 45.9 88.7 0.001
FSH 0.764 51.4 92.5 <0.001
E2 0.895 83.8 94.3 0.47
OFS 0.924 94.6 79.3 –
Fig. 1 The ROC curve compare between estradiol, Follicle-Stimulat-
ing hormone, age, and ovarian function score
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OFS (0.924) in ROC analysis was greater than that of age 
(0.673), FSH (0.764), and E2 (0.895), indicating that it has 
the greatest prediction value.
Interestingly, we found that the corpus luteum was still 
visible at 6–12  months in the ovarian tissue of patients 
with amenorrhoea who were receiving TAM. These 
findings indicate that these patients may retain ovarian 
function, and they may experience irregular ovulation 
or follicles that do not rupture (because of the relatively 
low LH levels) or are directly luteinised. Therefore, it is 
possible that TAM prolongs the life of the corpus luteum. 
For example, Swahn et al. (1989) studied the role of TAM 
on the corpus luteum of 16 women with normal ovarian 
function and found that their luteal phase was prolonged 
compared with that of the control patients. Furthermore, 
patients who received TAM exhibited elevated sex hor-
mone levels (e.g., FSH, oestrogen and 17-hydroxy-pro-
gesterone levels). Moreover, Cirpan et  al. (2008) tested 
the effects of TAM in rats and found that it did not 
increase the levels of Ki-67 (a cell proliferation marker) in 
the rats’ corpus luteum versus those of the control group. 
Therefore, this pathway may affect the extension of the 
luteal phase. The corpus luteum is the main source of 
progesterone; however, we did not evaluate this hormone 
in this study. Therefore, future studies should exam-
ine the effect of TAM on progesterone in patients with 
amenorrhoea. Those data may be useful in determining 
whether progesterone can be used to predict ovulation 
and restore ovarian function.
The most accurate method for determining ovarian 
function is through the pathological examination of serial 
sections of the entire ovary, which is labour-intensive and 
cannot be performed in clinical practice. We examined 
the largest ovarian area possible using consistent sam-
pling methods, yielding reliable results. Currently, for 
patients with cessation of menstruation after chemother-
apy, periodic monitoring of sex hormones cannot accu-
rately predict ovarian function, especially in those who 
use TAM because it significantly changes sex hormone 
levels, making it difficult to assess ovarian function. The 
OFS is a simple, effective and feasible method for eval-
uating ovarian function. However, our study’s sample 
size was limited. In the future, multi-centre studies with 
larger sample sizes should be conducted to further con-
firm and improve the OFS and provide a basis for future 
clinical assessments of ovarian function of breast cancer 
patients.
Conclusion
The OFS is expected to become a new simple and effec-
tive method for determining the ovarian function of 
women with breast cancer who have drug-induced 
amenorrhoea.
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